Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

• Status: Completed
• Trial end date: 2013-11-27
• Target enrollment: 0
• Participant gender: All

Summary

To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Co., Ltd.

Criteria

Inclusion criteria :

• Inoperable breast cancer

• Recurrent breast cancer

Exclusion criteria :

• Corresponding to contraindication of eribulin mesylate

• Not applicable to indications of eribulin mesylate

• Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs